表紙
市場調查報告書

焦點市場分析:肉瘤

Market Spotlight: Sarcoma

出版商 Datamonitor Healthcare 商品編碼 603965
出版日期 內容資訊 英文 57 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
焦點市場分析:肉瘤 Market Spotlight: Sarcoma
出版日期: 2019年12月31日內容資訊: 英文 57 Pages
簡介

2017年,全球肉瘤數量已達到413,300例,預計到2026年將增至485,100例。其中的百分之八十三是在軟組織中產生的骨外肉瘤,而百分之十七是惡性骨腫瘤。當前市場上有許多治療劑(主要是靜脈注射藥),以及活躍的臨床試驗和資本交易活動。就各國來看,美國市場掌握主導權,法國和以色列等市場也很活躍。

本報告提供全球肉瘤的治療藥的市場調查,彙整疾病的背景·概要,發病數的十年預測,主要的治療方法,主要的開發平台藥物概要,主要的已上市藥物趨勢,主要的資本交易趨勢 (授權合約,資產收購等),專利資訊,臨床試驗狀況等資料。

概要

要點

疾病的背景

  • 亞型

治療

  • 外科手術
  • 化療
  • 放射治療
  • 標靶治療

流行病學

  • 疾病的流行病學性的定義

已上市藥物

開發平台藥物

近來的主要市場活動和分析師的見解

今後主要的活動

法律規章上主要的事件

成功的可能性

授權合約·資產收購交易

母專利

商機

臨床實驗環境

  • 臨床試驗贊助者一覽:各狀況
  • 臨床試驗贊助者一覽:各期
  • 近來的事件

參考文獻

  • 處方資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0185529

This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were approximately 413,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 485,100 incident cases by 2026. Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (83%), while a smaller proportion were osteosarcomas and other malignant bone tumors (17%).

The approved drugs in the sarcoma space focus on a wide variety of targets. The majority of approved drugs are administered via the intravenous route, with two products being available in oral formulations.

The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II, with only one drug in the NDA/BLA stage.

Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular/subretinal/subconjunctival, intradermal, intramuscular, intraarterial, intratumoral, and topical formulations.

High-impact upcoming events in the sarcoma space comprise topline Phase II trial results for ADP-A2M4CD8 and an expected PDUFA date for tazemetostat.

The overall likelihood of approval of a Phase I sarcoma asset is 10.7%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been 17 licensing and asset acquisition deals involving sarcoma drugs during 2014-19. The largest deal during the period was the $1,150m strategic collaboration and licensing agreement signed in 2014 between Adaptimmune and GlaxoSmithKline to develop and commercialize Adaptimmune's NY-ESO-1 program.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 89% of trials in Phase I-II, and only 11% in Phase III-IV.

The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major EU markets, while Israel has the top spot in Asia

Clinical trial activity in the sarcoma space is dominated by completed trials. Merck & Co and Novartis have the highest number of completed clinical trials for sarcoma, with 19 trials each.

Merck & Co leads industry.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Chemotherapy
  • Radiation therapy
  • Targeted therapies

EPIDEMIOLOGY

  • Epidemiological disease definition

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • ASP7486 for Sarcoma (July 15, 2019)
  • Bempegaldesleukin for Sarcoma (June 3, 2019)
  • Tazemetostat for Sarcoma (June 3, 2019)
  • Lartruvo for Sarcoma (June 2, 2019)
  • Hensify for Sarcoma (April 4, 2019)
  • Lartruvo for Sarcoma (January 18, 2019)
  • Beleodaq for Sarcoma (January 17, 2019)
  • Tazemetostat for Sarcoma (September 24, 2018)
  • Yondelis for Sarcoma (June 4, 2018)
  • Xpovio for Sarcoma (June 1, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Epizyme Banks On ORR For Tazemetostat Accelerated Approval
  • Celgene Eyes Late 2019 Kaposi Sarcoma Submission For Pomalyst Following BTD
  • Nanobiotix's Hensify Earns CE Mark For Soft-Tissue Sarcoma
  • EU Safety Review Starts For Oral Anticoagulants
  • Lilly's Lartruvo Could Be Headed For Rare Accelerated Approval Withdrawal
  • No New Patients For Lartruvo In EU After Trial Failure

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • STA Acquires Australian, Asian Rights To Yondelis
  • Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of sarcoma, 2017-26
  • Figure 2: Incident cases of sarcoma, by age, 2017
  • Figure 3: Incident cases of sarcoma, by tumor type, 2017
  • Figure 4: Overview of pipeline drugs for sarcoma in the US
  • Figure 5: Pipeline drugs for sarcoma, by company
  • Figure 6: Pipeline drugs for sarcoma, by drug type
  • Figure 7: Pipeline drugs for sarcoma, by classification
  • Figure 8: Bempegaldesleukin for Sarcoma (June 3, 2019): Phase II - w/Nivolumab
  • Figure 9: Tazemetostat for Sarcoma (June 3, 2019): Phase II - INI1-Negative Tumors
  • Figure 10: Lartruvo for Sarcoma (June 2, 2019): Phase III - ANNOUNCE (w/Doxorubicin)
  • Figure 11: Yondelis for Sarcoma (June 4, 2018): Phase III - TSAR
  • Figure 12: Xpovio for Sarcoma (June 1, 2018): Phase II/III - SEAL
  • Figure 13: Key upcoming events in sarcoma
  • Figure 14: Probability of success in the sarcoma pipeline
  • Figure 15: Licensing and asset acquisition deals in sarcoma, 2014-19
  • Figure 16: Parent patents in sarcoma
  • Figure 17: Clinical trials in sarcoma
  • Figure 18: Top 10 drugs for clinical trials in sarcoma
  • Figure 19: Top 10 companies for clinical trials in sarcoma
  • Figure 20: Trial locations in sarcoma
  • Figure 21: Sarcoma trials status
  • Figure 22: Sarcoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of sarcoma, 2017-26
  • Table 2: Marketed drugs for sarcoma
  • Table 3: Pipeline drugs for sarcoma in the US
  • Table 4: ASP7486 for Sarcoma (July 15, 2019)
  • Table 5: Bempegaldesleukin for Sarcoma (June 3, 2019)
  • Table 6: Tazemetostat for Sarcoma (June 3, 2019)
  • Table 7: Lartruvo for Sarcoma (June 2, 2019)
  • Table 8: Hensify for Sarcoma (April 4, 2019)
  • Table 9: Lartruvo for Sarcoma (January 18, 2019)
  • Table 10: Beleodaq for Sarcoma (January 17, 2019)
  • Table 11: Tazemetostat for Sarcoma (September 24, 2018)
  • Table 12: Yondelis for Sarcoma (June 4, 2018)
  • Table 13: Xpovio for Sarcoma (June 1, 2018)
  • Table 14: Historical global sales, by drug ($m), 2014-18
  • Table 15: Forecasted global sales, by drug ($m), 2019-23
Back to Top